Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2014; 20(2): 509-517
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.509
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.509
Risk factor | Risk ratio | 95%CI | Pvalue | |
Lower | Upper | |||
Gender (male) | 0.38 | 0.03 | 4.24 | 0.42 |
Age (> 45 yr) | 1.22 | 0.15 | 12 | 0.85 |
Duration of disease (> 2 yr) | 0.98 | 0.09 | 9.18 | 0.98 |
Severity (severe) | 8.37 | 0.46 | 751 | 0.17 |
Extent of disease (total colitis) | 2.43 | 0.15 | 118 | 0.55 |
Apheresis use | 0.87 | 0.08 | 9.59 | 0.91 |
CNI use | 0.54 | 0.01 | 10.2 | 0.69 |
Ganciclovir use | 0.04 | 0.01 | 0.5 | 0.01 |
Dose reduction of corticosteroids | 0.76 | 0.03 | 13.1 | 0.85 |
Number of CMV Ag1 (> 3) | 3.77 | 0.53 | 42.3 | 0.19 |
- Citation: Inokuchi T, Kato J, Hiraoka S, Suzuki H, Nakarai A, Hirakawa T, Akita M, Takahashi S, Harada K, Okada H, Yamamoto K. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. World J Gastroenterol 2014; 20(2): 509-517
- URL: https://www.wjgnet.com/1007-9327/full/v20/i2/509.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i2.509